Ultrasound therapy for lateral epicondylitis. A double blind randomised placebo controlled trial

ISRCTN ISRCTN34475330
DOI https://doi.org/10.1186/ISRCTN34475330
Protocol serial number N0544103837
Sponsor Department of Health (UK)
Funder Cambridge Consortium - Addenbrooke's (UK)
Submission date
12/09/2003
Registration date
12/09/2003
Last edited
06/12/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Cathy Speed
Scientific

Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
Cambridge
CB2 2QQ
United Kingdom

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Scientific title
Study objectivesUltrasound therapy for lateral epicondylitis
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedLateral epicondylitis (tennis elbow)
InterventionTo evaluate the effects of ultrasound in the treatment of lateral epicondylitis. Adult subjects with lateral epicondylitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will be blinded. Outcome measures will be recorded at 6 weeks and at 9 months from baseline. These will include a forearm evaluation score and pain (primary measures), grip strength, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.
Intervention typeOther
Primary outcome measure(s)

Not provided at time of registration

Key secondary outcome measure(s)

Not provided at time of registration

Completion date11/09/2003

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit75 Years
SexAll
Target sample size at registration200
Key inclusion criteria200 18-75 year olds (PROJ)
Key exclusion criteriaDoes not match inclusion criteria
Date of first enrolment11/09/2000
Date of final enrolment11/09/2003

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Box No 204
Cambridge
CB2 2QQ
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/05/2006 Yes No